Seeking Alpha

Encouraging data from NewLink immunotherapeutic study

  • Data from a 25-patient Phase 2 clinical trial evaluating NewLink Genetics' (NLNK) dorgenmeltucel-L HyperAcute immunotherapy in combination with pegylated interferon-alpha 2b for advanced metastatic, progressive, refractory or recurrent melanoma shows that the combo is capable of inducing complete and durable clinical responses with tumor regression and immune activation.
  • Of the sixteen patients with Stage IV disease, two had a complete response as defined by RECIST criteria, one had stable disease and four had no evidence of disease (NED) after resection. Of the nine patients with stage II/III disease, three remained NED and one stage IIC patient had slow progressive disease (PD) with a single site resected is currently NED.
  • Twelve of the 25 subjects are still alive. All evaluable patients (21/21) seroconverted.
  • The complete response rate was 12.5% in patients with metastatic disease and the responses were durable.
  • Shares are up 10% premarket on fairly good volume.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs